title: [Prevention of recurrent amiodarone-induced hyperthyroidism by iodine-131].
abstract: Amioradone-induced hyperthyroidism is a common complication of amiodarone therapy. Although definitive interruption of amiodarone is recommended because of the risks of aggravation of the arrhythmias, some patients may require the reintroduction of amiodarone several months after normalisation of thyroid function. The authors undertook a retrospective study of the effects of preventive treatment of recurrences of amiodarone-induced hyperthyroidism with I131. The indication of amiodarone therapy was recurrent, symptomatic, paroxysmal atrial fibrillation in 13 cases and ventricular tachycardia in 5 cases (M = 14, average age 64 +/- 13 years). The underlying cardiac disease was dilated cardiomyopathy (N = 5), ischaemic heart disease (N = 3), hypertensive heart disease (N = 2), arrhythmogenic right ventricular dysplasia (N = 2) or valvular heart disease (N = 2). Two patients had idiopathic atrial fibrillation. An average dose of 576 +/- 184 MBq of I131 was administered 34 +/- 37 months after an episode of amiodarone-induced hyperthyroidism. Amiodarone was reintroduced in 16 of the 18 patients after a treatment-free period of 98 +/- 262 days. Transient post-radioiodine hyperthyroidism was observed in 3 cases (17%). Sixteen patients (89%) developed hypothyroidism requiring replacement therapy with L-thyroxine. There were no recurrences of amiodarone-induced hyperthyroidism. After 24 +/- 17 months follow-up, the arrhythmias were controlled in 13 of the 16 patients (81%) who underwent the whole treatment sequence. The authors conclude that preventive treatment with I131 is an effective alternative to prevent recurrence of amiodarone-induced hyperthyroidism in patients requiring reintroduction of amiodarone to control their arrhythmias.
authors.affiliation: Département de cardiologie, CHU, hôpital Sud, Amiens. hermida.jean-sylvain@chu-amiens.fr
authors.forename: J S
authors.initials: JS
authors.lastname: Hermida
authors.forename: G
authors.initials: G
authors.lastname: Jarry
authors.forename: E
authors.initials: E
authors.lastname: Tcheng
authors.forename: V
authors.initials: V
authors.lastname: Moullart
authors.forename: S
authors.initials: S
authors.lastname: Arlot
authors.forename: J L
authors.initials: JL
authors.lastname: Rey
authors.forename: C
authors.initials: C
authors.lastname: Schvartz
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000638:Amiodarone / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000188:drug therapy / Q000209:etiology; D005260:Female; D006331:Heart Diseases / Q000150:complications; D006801:Humans; D006980:Hyperthyroidism / Q000139:chemically induced* / Q000517:prevention & control / Q000532:radiotherapy; D007037:Hypothyroidism / Q000188:drug therapy / Q000209:etiology; D007457:Iodine Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012189:Retrospective Studies; D017180:Tachycardia, Ventricular / Q000188:drug therapy / Q000209:etiology; D013972:Thyrotropin / Q000097:blood; D013974:Thyroxine / Q000627:therapeutic use
chemical_list: D000889:Anti-Arrhythmia Agents; D007457:Iodine Radioisotopes; D013972:Thyrotropin; D000638:Amiodarone; D013974:Thyroxine